Search company, investor...

Sonexa Therapeutics


Debt - II | Alive

Total Raised


Last Raised

$2M | 10 yrs ago

About Sonexa Therapeutics

Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.

Headquarters Location

12555 High Bluff Drive

San Diego, California, 92101,

United States

Missing: Sonexa Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sonexa Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sonexa Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sonexa Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Sonexa Therapeutics News

Raising Funds: AnaptysBio, Sonexa, Eclipse, NextDx, Naviscan

Oct 18, 2011

XconomySan Diego —  There’s been a flurry of funding deals among San Diego life sciences companies in recent weeks, led by AnaptysBio, a six-year-old startup that named a new executive chairman and chief business officer just last week. Here’s a rundown of recent activity: —AnaptysBio, founded in 2005 with technology to discover and optimize potent antibodies to fight disease, has raised $8 million of a targeted $22 million financing, according to a recent filing with the Securities and Exchange Commission. The financing includes equity, warrants, and securities. The company raised almost $34 million four years ago in a Series B round led by Novo A/S, a Novo Group holding company wholly owned by the Novo Nordisk Foundation. San Diego’s Avalon Ventures also was an investor, and Avalon founder Kevin Kinsella remains on the startup’s board. Other investors include Frazier Healthcare Investors, Numenor Ventures, Alloy Ventures, and WS Investment Co. —Sonexa Therapeutics, a privately-held biotech developing new drug treatments for Alzheimer’s disease and related disorders, has raised $1 million of a planned $2.5 million in warrants and securities, according to a recently regulatory filing . Domain Associates led a $30 million Series A funding round in 2008, and Domain partner Eckard Weber is identified as CEO in the filing. Other investors include Alta Partners, Scale Venture Partners, AgeChem Venture Fund, and MC Life Science Ventures. —Eclipse Therapeutics, a biotech developing drugs that target cancer stem cells, has raised nearly $2.8 million of a planned $3 million in debt, warrants, and securities, according to a recent regulatory filing . In March, the company announced the close of $2 million in seed funding led by its founding investor, City Hill Ventures, and the filing indicates that the new funding is an extension of that deal. City Hill Ventures’ founding partner, Jonathan Lim, was named as the executive chairman in March. He was previously the CEO of San Diego-based Halozyme Therapeutics. Another recent filing shows Lim as the founder and funder of another San Diego startup, NextDx, which recently raised $250,000 of a planned $500,000 in  funding. —Naviscan, a San Diego startup developing organ-specific imaging technology that uses Positron Emission Tomography (PET) scanners, has expanded funding of a planned $363,000 round disclosed last month . Since then, Naviscan has raised a total of $830,000 of a planned $2.2 million financing that includes debt, warrants, and securities, according to a regulatory filing .

Sonexa Therapeutics Frequently Asked Questions (FAQ)

  • Where is Sonexa Therapeutics's headquarters?

    Sonexa Therapeutics's headquarters is located at 12555 High Bluff Drive, San Diego.

  • What is Sonexa Therapeutics's latest funding round?

    Sonexa Therapeutics's latest funding round is Debt - II.

  • How much did Sonexa Therapeutics raise?

    Sonexa Therapeutics raised a total of $40.45M.

  • Who are the investors of Sonexa Therapeutics?

    Investors of Sonexa Therapeutics include Alta Partners, Domain Associates, Scale Venture Partners, GeneChem Management and Mitsubishi Corporation Life Sciences Ventures.

  • Who are Sonexa Therapeutics's competitors?

    Competitors of Sonexa Therapeutics include Oligomerix, Elusys Therapeutics, Ocera Therapeutics, Probiodrug, Larimar Therapeutics and 11 more.

Compare Sonexa Therapeutics to Competitors


Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.


BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

Anagen Therapeutics

Anagen Therapeutics is a biotechnology company focused on therapies for androgen and nuclear receptor-related diseases. Specific targets for its products under development include prostate disease, cardiovascular disease, neurodegenerative disease and skin disease.

Protemix Logo

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

Alice Therapeutics

Alice Therapeutics is a biotechnology company.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.